Released Nov 12, 2026, after the close
10-Q filed Nov 12, 2026, 43 days after period end · 0001493152-26-051384
What the release said
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2027 ended September 30, 2026 and
Elite Pharmaceuticals reported consolidated revenues of $40.1 million for the three months ended September 30, 2026, an increase of $3.8 million or approximately 10.4% over the prior-year period.¶2
Income from operations was $9.9 million, an increase of $1.7 million or approximately 21% compared with the same period of the prior fiscal year.¶2
Management will host a conference call on November 13, 2026 at 11:30 AM EST to discuss the Second Quarter results and recent business developments.¶3¶4¶5¶6
- Consolidated revenues, three months ended September 30, 2026
- $40.1 million Increase of $3.8 million or approximately 10.4% compared with the same period of the prior fiscal year.¶2
- Income from operations, second quarter fiscal 2027
- $9.9 million Increase of $1.7 million or approximately 21% compared with the same period of the prior fiscal year.¶2
- Net income attributable to common shareholders, Second Quarter
- $17.3 million¶2
Same quarter
| Metric | Q2 2027 | Q2 2026 | Q2 2025 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $40.08M | $36.32M | $18.88M | $14.16M |
| Net Income | $17.32M | $13.70M | -$11.04M | $14.93M |
| EPS Diluted | $0.01 | $0.01 | -$0.01 | $0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Elite Pharmaceuticals Inc · CIK 1053369 · Engraved from SEC EDGAR